Aprezo 30 mg

Aprezo 30 mg contains Apremilast, which is the first advanced oral systematic treatment for Psoriasis in India. The medicine is a phosphodiesterase 4 (PDE4) inhibitor, which is useful in treating moderate to severe psoriasis. Glenmark pharmaceutical LTD is currently trading Aprezo 30 mg tablets. The advanced treatment addresses the limitations of the current treatments available in India to treat psoriasis. It is extremely beneficial for patients with an early stage of the disease progression.

Aprezo & its uses

Aprezo or Otezla 30 mg, an equivalent brand of Apremilast is an oral treatment which can be self-administered unlike some of the currently available injectable treatments, which have to be administered by a doctor. The drug is safe and has no effect on the liver and kidney as well as does not require diagnostic tests or screening as needed in case of other treatments. The medicine is safe and efficacious as compared to other therapies available in the market.

Glenmark has launched Apremilast 30 mg tablets in the hope that millions of patients will be able to live a better life with this revolutionary treatment. The study reveals that about 3% of the world population has some form of Psoriasis. India has become the largest patient pool and is estimated to have 33 million sufferers of Psoriasis. The medicine is especially discovered to revolutionize the treatment of these 33 million patients in the country. The oral treatment is convenient to administer and will help transform the psoriasis treatment regime in the country.

Possible Side Effects

The common side effects of Otezla 30 mg are nausea, vomiting, back pain, anorexia, diarrhea, and depression.